bpc 157 regulatory status not approved drug Sequential biopharmaceutical and barriers limiting BPC-157 TLDR; no. BPC-157 is a

It produces substantial weight loss averaging 15 to 16% over 68 weeks and has well-characterized cardiovascular benefits

Michael Duben, MD is a Board-Certified Endocrinologist with over 20 years of clinical experience, trained at Mount Sinai and Albert Einstein College of Medicine

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional and/or National Research Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards

Disclaimer: Always consult a healthcare professional before adjusting dosage or beginning any new supplement